IJCS | Volume 33, Nº2, March / April 2020

129 1. Malachias MVB, Souza WKSB, Plavnik FL, Rodrigues CIS, Brand oAA, Neves MFT, et al. 7a Diretriz Brasileira de Hipertens oArterial. Arq Bras Cardiol. 2016;107(3Suppl):1-83. 2. Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J HumHypertens. 2014;28(8):463-8. 3. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment. Circulation. 2008;117(25):510-26. 4. Ben AJ, Neumann CR, Mengue SS. Teste de Morisky-Green e Brief Medication Questionnaire para avaliar ades o a medicamentos. Rev Saúde Pública. 2012;46(2):279-89. 5. Gusm o JL, Ginani FG, Silva GV, Ortega KC, Mion Jr D. Ades o ao tratamento emhipertens o arterial sist lica isolada. Rev Bras Hipertens. 2009;16(1):38-43. 6. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74. 7. Ulbrich EM, Mantovani MF. Fatores preditivos para complicações em pessoas com hipertens o arterial sistêmica e ações para o gerencimento de cuidados da enfermagem na atenç o primária. [tese]. Curitiba: Universidade Federal do Paraná; 2015. 8. Krieger EM, Drager LF, Giorgi DM, Pereira AC, Barreto Filho JA, Nogueira AR, et al. Spironolactone Versus Clonidine as a Fourth- Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). Hypertension. 2018;71(4):681-90. 9. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. Resistant Hypertension Revisited: A Comparison of Two University-Based Cohorts. Am J Hypertens. 2005;18(5Pt 1):619-26. References Araújo & Aras Junior Therapeutic adherence and resistant hypertension Int J Cardiovasc Sci. 2020; 33(2):121-130 Original Article of secondary hypertension were investigated, which is also a limitation of the study. Comparison of studies of patients with RH is difficult due to the small number of studies that consider only this subgroup of hypertensive patients, as well as those that consider therapeutic adherence to evaluate the diagnosis of RH and its differentiation from pseudoresistance. 10,11 Considering adherence to the diagnosis of RH is fundamental, since poor adherence to therapy and RH do not coexist, because it must have good adherence to define SAH as resistant. 10 Thus, further studies focusing on this specific group of patients with RH are needed to improve therapeuticmanagement, blood pressure control and clinical outcomes. Conclusion The majority of patients included in the study showed good therapeutic adherence according to the Morisky scale. An analysis of the factors that could influence adherence, only the number of antihypertensive drugs had a statistically significant influence, while the epidemiological, anthropometric and clinical characteristics were statistically insignificant. The estimated prevalence of pseudoresistance was approximately 20%, considering the Morisky test, the therapeutic regimen used and ABPM. Authors’ contributions Research creation and design: Araújo LBS. Data acquisition: Araújo LBS. Data analysis and interpretation: Araújo LBS. Statistical analysis: Araújo LBS. Manuscript writing: Araújo LBS. Critical revision of the manuscript for intellectual content: Araújo LBS and Aras Junior R. Supervision/as the major investigator: Araújo LBS. and Aras Junior R. Potential Conflicts of Interest No potential conflicts of interest relevant to this article were reported. Sources of Funding There were no external funding sources for this study. Study Association This study is not associated with any thesis or dissertation work. Ethics approval and consent to participate This study was approved by the Ethics Committee of Hospital Ana Nery under protocol number 138371. All the procedures in this studywere in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study.